Sanofi inks a Korean alliance to develop a pneumococcal vaccine

Sanofi ($SNY) has partnered with South Korea's SK Chemicals to develop, produce and market a pneumococcal conjugate vaccine. The French Big Pharma is paying SK Chemicals $23 million up front, after which both companies will invest in the project. If development is successful, SK Chemicals will manufacture the vaccine at its plant in South Korea and retain exclusive rights to the product in its home market. The partners will share profits generated outside of Korea. Release